VivoSeq
Other

Safety and Efficacy

0

Pipeline Programs

225

Active Trials

319

Companies Involved

Safety and Efficacy is an early-stage landscape with 0 programs across 319 companies. The most active players are Novartis, Pfizer, Gilead.

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

70/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

1,758

clinical trials

Completed1,111 · 63%
Unknown status183 · 10%
Terminated170 · 10%
Recruiting130 · 7%
Withdrawn58 · 3%
Active, not recruiting56 · 3%
Other50 · 3%

Trial Activity

1758 trials

Metformin in Safety and Efficacy in Gouty Patients
Recruiting··Phase 2·NCT06924658·70 enrolled
Page 1 of 118

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)